SATURNE

SATURNE aims to address whether chemotherapy is effective in patients with characteristics out-with the eligibility criteria of historical clinical trials. It also aims to find out whether online decision tools (Adjuvant! Online and NHS predict) are valid and reliable tools for aiding chemotherapy decisions in Scottish patients. SATURNE also presents an opportunity to test the feasibility and validity of regression discontinuity design (RD), a new data analysis method from econometrics that may allow us to use existing healthcare records to estimate the effectiveness of chemotherapy in situations where randomised trials are not possible.

 Project summary: 

 

Chief Investigator: Dr Peter Hall (https://www.ed.ac.uk/profile/peter-hall)

Project management team:

• Dr Ewan Gray, University of Edinburgh (https://www.ed.ac.uk/profile/ewan-gray)
• Professor Joachim Marti, University of Lausanne (https://www.unil.ch/fbm/fr/home/menuinst/communication/nouveaux-professeurs/2017/marti-joachim.html)
• Dr David Brewster, NHS National Services Scotland (http://www.research.ed.ac.uk/portal/en/persons/david-brewster(5495ea71-926b-4f86-bca1-c8a9287abaa0).html)
• Professor Jeremy Wyatt, University of Southampton (https://www.researchgate.net/profile/Jeremy_Wyatt2)

 

Number and location of participating sites (by region/ country):  UK – No sites

 

Funder: CSO

Start and End date:

Of grant award: 01/02/2017

Of recruitment: N/A

 

Status: Complete

 

Recent outputs associated with this project:

Publications:

•  E Gray, J Marti, D Brewster, J Wyatt, D Cameron, PS Hall. Independent validation of the NHS PREDICT breast cancer prognostication and treatment benefit prediction tool using the Scottish cancer registry. 1^st UK International Breast Cancer Symposium. Breast Cancer Res Treat (2018)

 

• PS Hall, Linda Williams, C Dodds, E Gray, W Jack. National analysis of recurrence after early breast cancer in Scotland. 1^st UK International Breast Cancer Symposium.  Breast Cancer Res Treat (2018)

 

Conference Presentations:

• A natural experiment using Scottish clinical data to estimate the real-world effectiveness of adjuvant chemotherapy in breast cancer patients. Université de Lausanne CHUV (16th April 2018)
• Geographic and socioeconomic variation in breast cancer treatment in Scotland: an empirical analysis using linked patient-level data. Wennburg International Collaborative Spring Policy Meeting, Zurich (April 13th 2018)
• Independent validation of the NHS PREDICT breast cancer prognostication and treatment benefit prediction tool using the Scottish cancer registry. Interdisciplinary Breast Cancer Symposium, Manchester (January 15th 2018)
• Real-world evidence of the effectiveness of adjuvant chemotherapy for early stage breast cancer from Scottish routine data. Health Economist's Study Group (HESG) Winter Meeting. City University London, London (January 11th 2018)

Invited Presentations:

• A natural experiment using Scottish clinical data to estimate the real-world effectiveness of adjuvant chemotherapy in breast cancer patients. Centre for Health, Policy and Economics, University of Lucerne, Switzerland (April 2018)
• Measuring comorbidity with alternative definitions, an observational study of early breast cancer patients using routinely collected data. Usher Cancer Researcher's Group Seminar Series (November 2017)

Knowledge Exchange:

• Development of software code for the automatic calculation of NHS PREDICT prognostic scores for use by Scottish Cancer Networks. Working in collaboration with colleagues in the South East Cancer Network (SCAN) this was used to aid delivery of the Cancer Quality Performance Indicators dataset. The quality indicators are an important part of an NHS Scotland initiative to improve cancer care.

 

UK GDPR privacy statement:

 

Sponsor: University of Edinburgh, Old College, South Bridge, Edinburgh, EH8 9YL

Chief Investigator: Dr Peter Hall, Edinburgh Cancer Research Centre, IGMM, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU; 0131 651 8510; p.s.hall@ed.ac.uk

 

ECTU Involvement: Health Economics